EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Impact of Durvalumab on the Duration and Complexity of Corticosteroid Therapy for Pneumonitis After Chemoradiotherapy

Saori Murata, Hidehito Horinouchi, Momoko Morishita, Sawako Kaku, Yuki Shinno, Yusuke Okuma, Tatsuya Yoshida, Yasushi Goto, Noboru Yamamoto, Tairo Kashihara, Kae Okuma, Masahiko Kusumoto und 1 weitere

Clinical Lung Cancer · 2024

DOI: 10.1016/j.cllc.2024.06.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2024. Verfasst von Saori Murata und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan; Cancer Medicine, Cooperative Graduate School, The Jikei Univ…. Hauptthemen laut MEDLINE: Chemoradiotherapy, Antibodies, Monoclonal, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: It is unclear how the duration and tapering pattern of corticosteroid therapy for pneumonitis changed after the introduction of durvalumab consolidation therapy. METHODS: We retrospectively evaluated the medical records of patients diagnosed with nonsmall cell lung cancer who received chemoradiotherapy between January 2014 and December 2020. RESULTS: Data for 135 patients treated before durvalumab approval and 100 patients treated with durvalumab after its approval were analyzed. In both groups, more than 70% were male, with a median age of 66 y. Approximately 85% were smokers, and the most common tumor histology was adenocarcinoma. Most patients were treated with doses of 60 and 66 Gy (n = 127 [94%] vs. n = 95 [95%]). Among the patients treated with durvalumab, 57%, 38%, and 5% had grade 1, grade 2, and grade 3 pneumonitis; none had grade 4 or 5 pneumonitis. Patients treated with durvalumab exhibited a longer duration of corticosteroid therapy for pneumonitis (17 wk; range: 2-88 wk) than patients not treated with durvalumab (7 wk; range: 0.4-21 wk; P < 0.001). Pneumonitis relapse was more frequent in patients treated with durvalumab (n = 8; 23%) than in patients not treated with durvalumab (n = 2; 7%). Among the 8 patients treated with durvalumab, 2 had recurrent pneumonitis, 1 could not terminate corticosteroids. CONCLUSIONS: Our data show that durvalumab prolongs the duration of corticosteroid therapy and increases the complexity of corticosteroid tapering patterns. This study can help manage pneumonitis caused by immune checkpoint inhibitors and other drugs used after chemoradiotherapy in routine practice and clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChemoradiotherapyAntibodies, MonoclonalLung NeoplasmsCarcinoma, Non-Small-Cell LungAdrenal Cortex HormonesPneumoniaHumansMaleFemaleAgedRetrospective StudiesMiddle AgedAged, 80 and overAntineoplastic Agents, ImmunologicalAdultFollow-Up Studies

Stichwörter der Autor:innen

ChemoradiotherapyCorticosteroidDurvalumabNonsmall cell lung cancerPneumonitis

Substanzen

durvalumabAntibodies, MonoclonalAdrenal Cortex HormonesAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan; Cancer Medicine, Cooperative Graduate School, The Jikei University Graduate School of Medicine, Minato-ku, Tokyo, Japan.
  • Department of Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan. Electronic address: hhorinou@ncc.go.jp.
  • Department of Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
  • Department of Diagnostic Radiology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
  • Department of Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan; Department of Experimental Therapeutics, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
  • Department of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.

Zitieren

APA

Murata, S., Horinouchi, H., Morishita, M., Kaku, S., Shinno, Y., Okuma, Y., Yoshida, T., Goto, Y., Yamamoto, N., Kashihara, T., Okuma, K., Kusumoto, M., & Ohe, Y. (2024). Impact of Durvalumab on the Duration and Complexity of Corticosteroid Therapy for Pneumonitis After Chemoradiotherapy. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2024.06.009

Vancouver

Murata S, Horinouchi H, Morishita M, Kaku S, Shinno Y, Okuma Y, et al. Impact of Durvalumab on the Duration and Complexity of Corticosteroid Therapy for Pneumonitis After Chemoradiotherapy. Clinical Lung Cancer. 2024. doi:10.1016/j.cllc.2024.06.009

BibTeX
@article{Murata2024,
  author = {Murata, Saori and Horinouchi, Hidehito and Morishita, Momoko and Kaku, Sawako and Shinno, Yuki and Okuma, Yusuke and Yoshida, Tatsuya and Goto, Yasushi and Yamamoto, Noboru and Kashihara, Tairo and Okuma, Kae and Kusumoto, Masahiko and Ohe, Yuichiro},
  title = {Impact of Durvalumab on the Duration and Complexity of Corticosteroid Therapy for Pneumonitis After Chemoradiotherapy},
  journal = {Clinical Lung Cancer},
  year = {2024},
  doi = {10.1016/j.cllc.2024.06.009}
}
Kostenlos starten →